Document is current
Any future updates will be listed below
-
Authors
Centeno, Christopher J.
Berger, Dustin R.
Pelle, Andrew J.
Dodson, Ehren
Hernigou, Philippe
Murphy, Matthew B.
-
Funding
Funding for this research was provided by:
Université Paris-Est Créteil
- License Information
-
More Information
Article History
Received: 6 March 2026
Accepted: 10 March 2026
First Online: 21 March 2026
Declarations
:
: Not applicable.
: CJC reports professional leadership roles with Regenexx and clinical affiliation with the Centeno-Schultz Clinic, which provides orthobiologic treatments including platelet-rich plasma (PRP) for musculoskeletal conditions such as knee osteoarthritis. He is also an inventor on issued patents and/or patent applications assigned to Regenexx, LLC relating to platelet-based/orthobiologic technologies. PH reports a professional role as Medical Director of Clinical Research at Regenexx. DRB, ED, and MBM are employees of Regenexx. These relationships could be perceived as potential competing interests in relation to this systematic review and meta-analysis.
